Cornea/External Disease News

NEW ORLEANS — Nearly 90% of dry eye disease specialists surveyed use artificial tears and hot compresses as first-line treatment for meibomian gland dysfunction, according to a poster presented at Academy ’23.

Well now, it seems as though I ruffled more than a few feathers with my annual anti-inflammatory review last month.

Bruder Healthcare has launched Eyedration, a single-use, moist heat mask that helps maintain tear production in individuals with dry, tired eyes, the company announced in a press release.

NEW ORLEANS — Contact lenses may have a refractive therapeutic effect on residual higher order aberrations in select patients, according to a speaker at Academy ’23.

Eye care pharmaceutical company Harrow announced the completed transfer of new drug applications for Flarex, Natacyn, Tobradex ST, Verkazia and Zerviate, all of which were acquired in July and will now be launched under the company name.

NEW ORLEANS — New research in dry eye disease suggests the next few years will bring significant advancements in treatment for patients, according to a speaker at Academy ’23.

Aurion Biotech announced that the first participant has been dosed in its phase 1/2 trial of AURN001, an investigational cell therapy for treatment of corneal edema secondary to corneal endothelial dysfunction.

NEW ORLEANS — A single application of cryopreserved amniotic membrane effectively treated signs and symptoms of moderate to severe dry eye disease after just 2 days, according to Damon Dierker, OD, FAAO, at Academy ’23.

NEW ORLEANS — Research presented at Academy ’23 demonstrated that perfluorohexyloctane, which is indicated for dry eye disease, reduces corneal staining up to four times more than saline.

The Twin Cities Ocular Surface Disease Symposium, Oct. 21-22 in Minneapolis, will include 12 hours of COPE continuing education credit and feature hands-on workshops with key devices and the latest in ocular surface disease technology.